BiliaryTractCancer near Rego Park, NY

Biography: Dr. Chris Hackett received his BS in Biological Sciences from Stanford University in 2000. After doing biomedical research in industry and academia, he then pursued graduate studies in cancer genomics at the University of California, San Francisco, where he earned his PhD in 2010. Seeking to become a physician-scientist, he then earned his medical degree (MD) from the University of Minnesota in 2014. He then completed his Internal Medicine Residency at NewYork-Presbyterian/Weill Cornell Medical Center, followed by a fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center (MSK), where he focused on solid tumor oncology in the clinic and carried out laboratory research to design T cell therapies for cancer. Following fellowship, Dr. Hackett was an attending on the Cellular Therapeutics Service at MSK, where he focused on treating patients with CAR T cells, Tumor Infiltrating Lymphocytes (TIL) and other cell therapies. In 2023, he joined the Bone Marrow Transplant Service at Weill Cornell Medicine and NewYork-Presbyterian Hospital, where he continues to both treat patients with cellular therapies and conduct research to develop new cell therapies for solid tumors.

Care Philosophy: I am a medical oncologist specializing in the treatment of patients with genitourinary malignancies (including prostate, bladder, testes, and kidney cancers). My clinical and translational research focuses on development of new treatment strategies for patients. In particular, I am studying the genetics of prostate cancer, and I am involved in developing personalized treatment approaches for patients based on their cancer's specific molecular alterations. My clinical practice and research rely on close collaborations with clinicians, scientists, and physician scientists from multiple disciplines including pathology, urology, radiology, radiation oncology, computational biology, pharmacology, and medical oncology. Most recently, we have expanded these clinical and research efforts across cancer types as part of our new Institute for Precision Medicine

Biography: Nicole D. Goulet is a Trauma and Acute Care Surgeon. Dr. Goulet earned her undergraduate degree from Smith College. She completed her medical educationand residency at University of Connecticut. She then went on to complete her Trauma and Critical Care Fellowship and her first year in practice at Rutgers University in Newark, NJ before she began working at NYU Langone in 2018. She served as the Director of the Surgical Intensive Care Unit in Brooklyn, NY for the past three years.Dr. Goulet is one of the founders of the Association of Out Surgeons and Allies (AOSA) and was the Founding President. She is also a member of several trauma organizations including the American Association for the Surgeryof Trauma (AAST) and Eastern Association for the Surgery of Trauma (EAST) as well as the Association for Academic Surgery (AAS) where she serves on Diversity, Equity and Inclusion (DEI) committees. She has published several articles on diversity and equity in surgery which is her primary research focus.

Biography: Ghaith Abu-Zeinah, MD, is an Assistant Professor in Medicine at Weill Cornell Medical College and an Assistant Attending Physician at the NewYork-Presbyterian Hospital. Dr. Abu-Zeinah earned his M.D. with academic distinction from the Weill Cornell Medical College in Qatar in 2013. He completed his residency training in Internal Medicine (2016) and fellowship training in Hematology/Oncology (2019) at the NewYork-Presbyterian Hospital/Weill Cornell Medicine in New York City.Dr. Abu-Zeinah is a Hematologist and Oncologist with a specialty practice in Myeloproliferative Neoplasms (MPN). His laboratory and clinical research is focused on identifying and developing therapies that target the malignant stem cells in patients with MPN. He received several awards for his work and presented at national conferences including the International Congress on Myeloproliferative Neoplasms and the American Society of Hematology. He has joined the Richard T Silver MPN Center as a physician-scientist both treating patients and conducting research.

Biography: Elizabeth Gorman, MD is an Assistant Professor of Surgery in Weill Cornell Medicine's Division of Trauma, Burns, Acute and Critical Care Surgery. Dr. Gorman graduated Cum Laude from Dartmouth College. Subsequently, she received her medical degree from University of Texas Southwestern Medical School. She completed her general surgery residency at NYU Langone Medical Center and spent an additional year as a clinical research fellow. She then pursued fellowship training in Surgical Critical Care and Acute Care Surgery at Rutgers New Jersey Medical School. Dr. Gorman is board certified in General Surgery and Surgical Critical Care.View Research Publications

Biography: Alexandra Gomez Arteaga, M.D., is Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine/New York-Presbyterian Hospital. She specializes in the care of patients with hematological malignancies and other disorders who need a blood or bone marrow stem cell transplant or cellular therapies.Dr. Gomez received her M.D. (Valedictorian) from Los Andes University in Bogota, Colombia, in 2011. She completed her Internal Medicine residency at the University of Miami/Jackson Memorial Hospital and her Hematology/Oncology fellowship at Weill Cornell Medicine/New York-Presbyterian Hospital, where she also served as Chief Fellow. Subsequently, she completed an advanced fellowship in Bone Marrow Transplantation at Memorial Sloan Kettering Cancer Center. Upon completion of her training, Dr. Gomez was recruited back to Weill Cornell Medicine/New York-Presbyterian Hospital to join the faculty of the Bone Marrow Transplant Program.Dr. Gomez's main research focus is relapse prevention strategies and management of disease relapse after a stem cell transplant. She has published in leading internationally circulated peer-reviewed journals, among them Cancer, Biology of Blood and Marrow Transplantation, Bone Marrow Transplantation, the American Journal of Hematology, Leukemia & Lymphoma. She is a member of the American Society for Transplantation and Cellular Therapy (ASTCT), the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), and the Society for Immunotherapy of Cancer (SITC).

Care Philosophy: Alexander J. Chou, MD, is a pediatric oncologist specializing in the treatment of pediatric sarcomas, rare cancers of the bone and soft tissues at Children's Hospital at Montefiore. Dr. Chou, along with his colleagues, provides state-of-the-art therapies to patients with sarcomas in a comprehensive and multidisciplinary setting. Dr. Chou is the Clinical Director of the Pediatric Sarcoma Service at the Children's Hospital at Montefiore and an Associate Professor of Pediatrics at the Albert Einstein College of Medicine.Dr. Chou earned his Bachelor of Arts in Biology in 1994 at the University of Pennsylvania. In 1998, he received his Doctor of Medicine at Cornell University Medical College in New York City. Following this, he completed an internship and residency in Pediatrics at New York-Presbyterian Hospital/Weill Cornell Medical Center in New York City.

Biography: Dr. Evelyn Cantillo completed her undergraduate studies at Cornell University prior to pursuing a Master of Public Health degree at Columbia University. She subsequently earned a medical degree at the Albert Einstein College of Medicine, graduating with special distinction in Obstetrics and Gynecology. Her residency training in Obstetrics and Gynecology was completed at Tulane University, followed by a fellowship in Gynecologic Oncology and Breast Disease at the Women & Infants Hospital/Brown University.Dr. Cantillo's practice encompasses the surgical and medical management of the broad spectrum of gynecologic malignancies including uterine, ovary, cervix, vulva, and vagina. She is extensively trained in minimally invasive surgical techniques using traditional laparoscopy, as well as robotic platforms, for gynecologic cancer and complex benign conditions.Dr. Cantillo believes that every woman with gynecologic cancer should have access to the full complement of care. With this in mind, her aim is to expand access to clinical trials should this become necessary. She is a member of the New Investigators Committee of the national NRG (formerly Gynecologic Oncology Group/GOG). It's important to her that all populations be afforded the same opportunities and treatment.Her interests also include medical education. She has received numerous teaching and surgical awards during residency and fellowship training and has presented her research at regional and national conferences.

Biography: Dr. Laura S. Munoz Arcos is an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine and an Assistant Attending Physician at NewYork-Presbyterian Hospital.Dr. Munoz Arcos earned her medical degree from Universidad del Valle in Colombia, her home country. She then completed an internal medicine residency at Montefiore Medical Center/Albert Einstein College of Medicine in the Bronx, NY, followed by a Hematology and Oncology fellowship at Weill Cornell Medicine/NewYork-Presbyterian Hospital, where she served as Chief Fellow in her final year. During her fellowship, Dr. Munoz Arcos gained extensive clinical experience in treating all types of breast cancer while conducting translational research on liquid biopsy in breast cancer at Dr. Massimo Cristofanilli's laboratory. Her research focuses on identifying predictors of response to therapy in hormone receptor-sensitive metastatic breast cancer. In recognition of her work, she received the 2023 Conquer Cancer American Society of Clinical Oncology (ASCO) Young Investigator Award, a prestigious honor granted to only 100 recipients annually. Following the completion of her fellowship, Dr. Munoz Arcos joined the Division of Hematology and Medical Oncology as a faculty member, where she is focused on the treatment of breast cancer.

Biography: Dr. Vered Stearns completed the equivalent of a B.S. degree at the Tel Aviv University, Sackler Faculty of Medicine in 1989. After relocating to the United States, Dr. Stearns transferred to and graduated from the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School with a medical degree (M.D.) in 1992. She completed a residency in Internal Medicine and a fellowship in Medical Oncology at the Georgetown University where she developed an interest in translational breast cancer research and spent two additional years as a research fellow. Dr. Stearns was a faculty member at the Lombardi Comprehensive Cancer Center and the Georgetown University, and at the University of Michigan Comprehensive Cancer Center in Ann Arbor, Michigan before joining the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in 2002. She remained at Johns Hopkins and served in a variety of roles, including co-Director of the Breast Cancer Program, co-Director of the Breast and Ovarian Cancer Program, Director, Women's Malignancies Disease Group and inaugural Medical Director of the Under Armour Breast Health Innovation Center, until being recruited to Weill Cornell Medicine and New York-Presbyterian Hospital in 2023. At Weill Cornell Medicine, Dr. Stearns is Director of Translational Breast Cancer Research at the Department of Medicine, and Associate Director for Clinical Services at the Meyer Cancer Center. Her role in the Meyer Cancer Center will allow her to develop programs and to mentor team members across diseases throughout Manhattan, Brooklyn and Queens.Dr. Stearns's long-term research goal is to improve current therapies by individualizing strategies for the treatment and prevention of breast cancer. The main focus of Dr. Stearns's research includes the utilization of biomarkers to predict response to standard regimens used to treat and prevent breast cancer, and to introduce new interventions. Dr. Stearns and colleagues from the Consortium On Breast Cancer Pharamcogenomics (COBRA) Group were the first to evaluate the role of genetic variants in candidate genes such as CYP2D6 in tamoxifen metabolism, safety, and efficacy. This work has been extended to evaluate the role of genetic variants in aromatase inhibitor associated outcomes. She has also conducted clinical investigations of epigenetic modifying agents across the breast cancer continuum. She is evaluating whether histone deacetylase inhibitors enhance response to immunotherapy. Having demonstrated that methylation markers predict breast cancer risk, she is evaluating whether natural compounds can reverse these modifications.Dr. Stearns has received numerous grants and awards to fund her innovative research. She was a recipient of early career awards including a Clinical Research Training Grant from the American Cancer Society, and was one of the first five recipients of the prestigious Damon Runyon Clinical Investigator Award. Subsequently she was the inaugural recipient of the American Society of Clinical Oncology (ASCO) Advanced Clinical Research Award.She served as a Board Member of the National Accreditation Program for Breast Centers (NAPBC) for the American College of Surgeons (ACS), and was elected in 2020 as Fellow of the American Society of Clinical Oncology (FASCO). Her work has already had a positive impact on the lives of many women, and in 2017, Dr. Stearns was selected by Forbes as one of 27 top breast cancer oncologists in the United States. Dr. Stearns is Vice Chair of the NRG Translational Science Committee, and Co-Chair of the NRG Breast?Translational?Working Group. In these roles, she works closely with Group members as they investigate correlative biomarkers obtained through breast cancer trials.